/
/
/
Dr Madeleine Hinwood

Dr Madeleine Hinwood

Conjoint Lecturer, University of Newcastle

Research Programs

NHMRC Ideas Grant 2021 | Assessing the impact of P2Y12 receptor inhibitor drugs on cognitive changes post-stroke using target trial methodology
Launching FocUS-R, a longitudinal stress and health monitoring survey started right here in the Hunter, in early 2024. First batch of results coming soon!

Dr Madeleine Hinwood is a mid-career researcher and methodologist, specialising in the translation of causal inference methods into applications across public health. She has worked between academic, industry, and government in health technology assessment in a consulting role at the University of Newcastle, and most recently as a biostatistician and senior epidemiologist at the Hunter Medical Research Institute.

She has secured more than $15 million in consulting and research funding over her career. She has published over 24 journal articles, and 25 health technology assessment reports for the federal Department of Health.

Dr Hinwood maintains a number of established national and international collaborations, including the NHMRC Centre of Excellence in Stroke Rehabilitation and Brain Recovery, and the Sahlgrenska Institute at the University of Gothenburg, Sweden, in order to examine the impacts of immune-modifying exposures, including stress, prescribed drugs, and socio-cultural factors on brain repair outcomes post-stroke. Dr Hinwood has maintained strong cross-faculty collaborations at the University of Newcastle.

Madeleine is currently mentoring 3 PhD students, and has supervised several undergraduate research projects in Medicine. She has supervised one PhD student to completion, and he is currently undertaking a postdoctoral fellowship at the London School of Economics. She has contributed to strong methodological training in all students, including epidemiology, statistics, and evidence synthesis.

Dr Hinwood’s work has had wide ranging impact. During her time in health technology assessment at the University of Newcastle, she evaluated over 25 submissions for novel medicines, ultimately impacting their pricing and availability on the Pharmaceutical Benefits Scheme. Her independent research work has made significant contributions to the fields of neuroimmunology, and more recently consumer-focused health systems research and applied methodology.